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Abstract
The difference between total lung capacity (TLC) by body plethysmography and 
alveolar volume (VA) from the single-breath lung diffusing capacity measurement 
provides an index of ventilation distribution inequalities in COPD. The relevance of 
these abnormalities to dyspnea and exercise intolerance across the continuum of 
disease severity remains unknown. Two-hundred and seventy-six COPD patients 
distributed across GOLD grades 1 to 4 and 67 healthy controls were evaluated. The 
“poorly communicating fraction” (PCF) of the TLC was estimated as the ratio (%) 
of TLC to VA. Healthy subjects showed signifi cantly lower PCF values compared 
to GOLD grades 1 to 4 (10 ± 3% vs. 17 ± 8% vs. 27 ± 10% vs. 37 ± 10% vs. 56 ± 
11%, respectively; p < 0.05). Pulmonary gas exchange impairment, mechanical 
ventilatory constraints and ventilation-corrected dyspnea scores worsened across 
PCF tertiles (p < 0.05). Of note, GOLD grades 1 and 2 patients with the highest PCF 
values had pronounced exercise ventilatory ineffi ciency and dyspnea as a limiting 
symptom. In fact, dyspnea was a signifi cant contributor to exercise limitation 
only in those with “moderate” or “extensive” PCF (p < 0.05). A receiver operating 
characteristics curve analysis revealed that PCF was a better predictor of severely 
reduced maximal exercise capacity than traditional pulmonary function indexes 
including FEV1 (area under the curve (95% confi dence interval) = 0.85 (0.81–0.89), 
best cutoff = 33.4 %; p < 0.01). In conclusion, PCF is a readily available functional 
marker of gas exchange and mechanical abnormalities relevant to dyspnea and 
exercise intolerance across the COPD grades.
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Introduction
Traditional spirometric measurements, such as forced expiratory fl ow rates, 
are poorly predictive of important clinical outcomes such as dyspnea and 
exercise intolerance in COPD (1). It is therefore desirable to develop novel 
physiological markers that better predict exercise intolerance, particularly in 
patients with milder airway obstruction (2,3). 
Adequate distribution of inhaled air is paramount to minimize the work 
of breathing and optimize the effi  ciency of the lung as a gas exchanger (4). 
In patients with COPD, there is well-established evidence that airfl ow distri-
bution inequalities are sensitive markers of early physiological dysfunction 
(5,6) and disease progression (7). Th ese abnormalities are likely to further 
deteriorate under conditions of increased respiratory frequency and higher 
fl ow rates (8), e.g., during physical exercise. In this context, the presence of 
ventilation distribution abnormalities at rest might reasonably be associated 
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with exaggerated ventilation-perfusion abnormalities 
during exercise. Th us, the associated increase in ventila-
tory requirements would be expected to have negative 
consequences for dyspnea and exercise tolerance (9). 
It is of clinical interest, therefore, to identify a marker 
of disturbed gas distribution at rest that would help to 
predict these relevant outcomes across the whole range 
of COPD severity. 
It has long been recognized that inert gases dilution 
tests might provide valuable information about inspired 
gas distribution abnormalities and trapped gas volume 
(10). Th ese tests are based on the logical assumption 
that the fraction of a highly insoluble gas (e.g., helium, 
methane) recovered at end expiration is inversely related 
to the number of lung units eff ectively participating in 
alveolar ventilation (11). Single breath techniques pro-
vide the simplest approach to estimate the poorly com-
municating fraction of total lung capacity (PCF, % TLC). 
(Although the denomination “non-communicant” vol-
ume has been used in the past, scarcely ventilated uni-
ties better represent a “poor communicant” lung volume 
as air from non-ventilated areas that remain perfused is 
readily absorbed by the fl owing venous blood.) 
In practice, they are routinely used to assess the  mixing 
gas volume for diff using capacity of the lung for carbon 
monoxide (DLCO) i.e., “alveolar volume” (VA) (12). Using 
plethysmographically derived measurements of TLC as 
a frame of reference, PCF can be readily estimated, e.g., 
1 – (VA/TLC) (%) (13–15).
Th e current study, therefore, is the fi rst to systemati-
cally investigate whether PCF—as an indirect measure 
of unequal ventilation distribution at rest and trapped 
gas volume (16–18)—would add to standard pulmonary 
function tests in predicting ventilatory constraints, arte-
rial oxygen desaturation, and poorer exercise capacity 
across the continuum of airway obstruction in COPD. 
We hypothesized that regardless of disease severity 
PCF would relate to impaired dynamic mechanics and 
pulmonary gas exchange, and thus to the intensity of 
dyspnea and exercise intolerance. Confi rmation of the 
study hypotheses would lend novel support for the use 
of PCF as a physiological marker of clinical outcomes in 
both clinical and research settings. 
Methods
Subjects and design
Th is study involved a retrospective analysis of data col-
lected between 2000 and 2012 at the Respiratory Inves-
tigation Unit, Queen’s University and Kingston General 
Hospital, Kingston, ON, Canada. All patients had an 
established diagnosis of COPD according to current cri-
teria (19), and they had been followed by the same res-
pirologist (DOD) in a COPD-dedicated clinic for at least 
6 months. Patients and controls had taken part in ethically 
approved research studies in which pulmonary function 
tests and an incremental cycle cardiopulmonary exercise 
test were performed as part of the study entry assessment. 
Inclusion criteria for both groups included men and 
women 40 to 80 years of age, availability of both TLC 
by body plethysmography and VA from DLCO measure-
ments, and lack of orthopedic, neuromuscular, cardiac, 
and metabolic conditions precluding the patient to 
safely undertake an incremental exercise test. Inclusion 
criteria for the COPD group in the afore-mentioned 
studies were consistent regarding: a) presence of short-
ness of breath on exertion and/or daily life, b) absence 
of asthma or any lung disease other than COPD, and 
c) absence of previous exacerbation in the preceding 
6 weeks. Th e Queen’s University and Affi  liated Teach-
ing Hospitals Research Ethics Board approved the use 
of these anonymous data sets and waived the need for 
patient informed consent (DMED-1659-13).
Procedures
Lung function tests
Spirometry, body plethysmography, and DLCO were 
performed by experienced researchers/technicians 
using automated testing equipment (2130 spirometer 
with 6200 Autobox DL or V6200 Autobox; SensorMed-
ics; Yorba Linda, California) (20,21). All short-acting 
and long-acting bronchodilators were withdrawn for 
at least 4 hours and 12 hours, respectively. As patients 
had taken part in studies with diff erent bronchodilators, 
GOLD grades were defi ned according to pre-broncho-
dilator FEV1. VA was derived from the single breath 
DLCO maneuver: methane as a tracer (0.3%), inspired 
volume > 90% of the largest vital capacity in less than 
2.5 seconds (4 seconds in COPD), breath-hold time 
(10 ± 2 seconds) (22), sample collection time < 3 seconds, 
washout volume of 0.75 L (0.5 L when vital capacity 
< 2 L), appropriate clearance of dead space, and sample 
gas of 0.75 L (0.5 L when vital capacity < 1 L) (21). 
Exercise tests
Symptom-limited incremental exercise testing (10–20 
W/min) was conducted on an electronically braked 
cycle ergometer using the Vmax229d Cardiopulmonary 
Exercise Testing System (SensorMedics) (23). Minute 
ventilation (V.  E, L/min), oxygen uptake (V.  O2, L/min), 
carbon dioxide output (V.  CO2, L/min) and tidal volume 
(VT, L) were averaged over the last 30 seconds at peak 
exercise. Oxygen saturation was measured by pulse 
oximetry (SpO2, %). Breathlessness and leg eff ort were 
rated according to the 10-point Borg category-ratio 
scale (24). 
End-inspiratory lung volume (EILV, L) was calculated 
as end-expiratory volume (from inspiratory capacity) +
VT and related to TLC. Peak V.  E was also expressed 
relative to maximal ventilatory capacity (MVC (L/min) =
FEV1 × 35 (23). Due to the expected diff erences in maximal 
exercise capacity among the COPD grades,  end-exercise 
EILV/TLC (× 100) and dyspnea scores were corrected for 
the ventilatory demand (peak V.  E) and peak V.  E /MVC 
corrected for the maximal metabolic stress (V.  O2). Peak 
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V.  O2 < 1 L/min and/or < 60% predicted (25) were a priori
selected to indicate severe exercise limitation (23, 27–28).
Statistical analysis
Values are reported as means ± SD unless otherwise 
specifi ed. A p value of < .05 was considered signifi cant 
in all analyses. Comparisons across subgroups were per-
formed using analysis of variance (ANOVA) with post-
hoc testing of signifi cant variables carried out using t tests 
with Bonferroni adjustment for multiple comparisons. 
χ2 analysis tested the association between categorical 
variables. According to variables distribution, Pearson’s R 
or Spearman’s ρ tested the correlation between continu-
ous variables. Part (semi-partial) correlation calculated 
the correlation between PCF and TLC or VA in a multi-
variable regression analysis (asymptotic regression). An 
ROC curve analysis was used to contrast the diagnosis 
performance of the pulmonary function tests in predict-
ing a severely reduced maximal exercise capacity.
Results
Subject characteristics
Data from 316 COPD patients and 69 healthy controls 
were reviewed. TLC by body plethysmography and/
or VA from DLCO measurements were not available 
in 40  patients and 2 controls. Th erefore, 276 COPD 
patients distributed across GOLD grades 1 to 4 and 
67 healthy controls fulfi lled the inclusion criteria. 
Patients and controls were well matched for age (68.3 ±
6.4 yrs vs. 66.7 ± 7.0 yrs), gender (153/276 (53.6 %) 
vs. 36/67 (53.6%) males) and body mass index (27.2 ±
4.7 kg/m2 vs. 26.1 ± 3.2 kg/m2) (p > 0.05).
PCF distribution
Controls showed signifi cantly lower PCF values com-
pared to COPD grades 1 to 4 (10 ± 3% vs. 17 ± 8 vs. 27 
± 10 vs. 37 ± 10 vs. 56 ± 11%, respectively; p < 0.05 for 
all between-group comparisons. Th ere was, however, a 
wide distribution of PCF within a given GOLD grade 
(Figure 1). Only 2 controls showed a PCF value above 
17% with 91.4% of the values ranging from 5% to 15%. 
Using tertiles as a frame of reference (N = 92 in each 
group), patients were separated into “mild” (≤ 23%), 
“moderate” (24–33%) and “extensive” (≥ 34%) PCF. 
PCF Determinants
PCF was more closely related to lower VA% predicted 
than higher TLC% predicted (Figure 2). In fact, non-lin-
ear regression analysis (asymptotic regression) revealed 
that the semi-partial correlation coeffi  cients for PCF 
prediction were larger for VA% than TLC% (–0.79 vs. 
0.58; R2 = 0.90; p < 0.001). Age, gender and body mass 
Figure 1. Boxplot (median, interquartiles and range) of PCF in healthy controls and 
COPD patients according to GOLD grades.
Figure 2. Signifi cant correlations between % predicted total lung capacity (TLC) 
(panel A) and alveolar volume (VA) (panel B) with PCF in COPD patients grades 1 
to 4 (N = 276). Panel C shows the non-linear relationship (asymptotic regression) 
between %TLC-%VA differences and PCF.
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index showed no signifi cant relationship with PCF 
(p > 0.05).
PCF severity and functional impairment
PCF correlated signifi cantly with the main resting func-
tional indexes across disease grades (p < 0.05); however, it 
varied substantially for a given FEV1, sRaw, RV and DLCO
in individual patients (Figure 3). Markers of exercise 
impairment—including greater operational lung volumes 
and dyspnea—worsened across the PCF tertiles either in 
the whole sample (Table 1) or within GOLD grades 1 to 3 
(Table 2) (p < 0.05). End-exercise dyspnea scores were at 
least equivalent to leg eff ort only in patients with “moder-
ate” or “extensive” PCF (Figure 4). Forty patients (14.5%) 
showed peak SpO2 ≤ 90%: the fraction of patients with 
SpO2 ≤ 90% increased across PCF tertiles (3/92 (3.2%), 
12/92 (13.0%) and 25/92 (27.1%) for “mild,” “moderate” 
and “extensive” PCF, respectively (p < 0.05). 
Th ere were signifi cant associations between “exten-
sive” PCF and severe reductions in peak exercise 
 capacity (specifi city, positive likelihood ratio and post-
test probability = 92.1%, 6.31 and 90%, respectively). 
In fact, a ROC curve analysis revealed that PCF was a 
better predictor of severe reductions in peak exercise 
capacity than FEV1, RV, and DLCO (Figure 5). 
Considering the potential for PCF to show early 
signs of airways disease in milder COPD (2, 9–12), 
we performed a more detailed analysis within GOLD 
grades 1 and 2. Compared to their counterparts with 
PCF ≤ 17%, patients with higher PCF showed greater 
V.  E/V.  CO2 and dyspnea/V.  E at peak exercise (GOLD 1: 
31 ± 3 vs. 35 ± 7 and 0.07 ± 0.03 units/L/min vs. 0.11 
± 0.04 units/L/min; GOLD 2: 33 ± 2 vs. 36 ± 4 and 
0.06 ± 0.04 units/L/min vs. 0.13 ± 0.05 units/L/min, 
respectively; p < 0.05). All GOLD 1 patients (N = 14) 
and 33/36 (91.6%) GOLD 2 patients with pronounced 
exercise ventilatory ineffi  ciency (V.  E/V.  CO2> 40) (23) 
showed PCF > 17%. In contrast, all patients from both 
groups with normal V.  E/V.  CO2 (<34) (23) had PCF ≤ 
17% (p < 0.01). 
Figure 3. Non-linear correlations of PCF with FEV1, (panel A) and specifi c airway resistance (panel B) and linear correlations of PCF with residual volume (panel C) and lung 
diffusing capacity for carbon monoxide (panel D) in COPD patients grades 1 to 4 (N = 276). Lines represent the cutoffs for PCF tertiles.
CO
PD
 D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
Qu
ee
n's
 U
niv
ers
ity
 on
 09
/20
/14
Fo
r p
er
so
na
l u
se
 o
nl
y.
 Ventilation distribution and exercise intolerance in COPD 5
www.copdjournal.com
Discussion
Th is is the fi rst study to evaluate the relevance of 
increased “poorly communicating” fraction of TLC 
(PCF) as a marker of exercise impairment in a large 
group of patients with COPD, GOLD grades 1 to 4. Our 
main results support the study hypotheses as increased 
PCF was associated with higher operational lung vol-
umes, arterial oxygen desaturation and exercise-related 
dyspnea scores at peak exercise across the continuum 
of airway obstruction. Of note, increased PCF was a 
better predictor of severe reductions in exercise toler-
ance than traditional functional indices including FEV1. 
Th ese data provide novel evidence that PCF adds useful 
Table 1. Selected resting and peak exercise variables in COPD patients 
separated by PCF tertiles
“Mild” PCF
(N = 92)
“Moderate” PCF
(N = 92)
“Extensive” 
PCF (N = 92)
Rest
FEV1 (% pred) 83.4 ± 18.9* 59.7 ± 19.6† 39.2 ± 16.9
RV (% pred) 109.9 ± 26.7* 144.9 ± 39.9† 208.4 ± 62.9
IC (% pred) 103.1 ± 20.7* 85.5 ± 19.3† 66.8 ± 19.6
IC/TLC 0.47 ± 0.09* 0.38 ± 0.08† 0.28 ± 0.08
sRaw (cmH2O/L/s)/L) 10.7 ± 4.5* 18.4 ± 8.7† 30.8 ± 14.7
DLCO (% pred) 81.1 ± 21.7* 66.5 ± 20.6† 52.1 ± 18.8
Peak exercise
V
.
O2
 % pred 86.4 ± 24.6* 76.3 ± 21.9† 56.1 ± 21.1
< 1 L/min 5.0* 29.5† 68.2
< 60% pred 13.2* 26.4† 60.4
V
.
 E/V
.
CO2 34 ± 5* 36 ± 7
† 39 ± 9
(EILV/TLC)/V
.
E 1.61 ± 0.49* 2.31 ± 0.68
† 3.38 ± 1.23
(V
.
 E/MVC)/ V
.
O2 0.50 ± 0.18* 0.74 ± 0.29
† 1.17 ± 0.52
Dyspnea/ V
.
 E 0.09 ± 0.04* 0.12 ± 0.06
† 0.19 ± 0.09
p < 0.05: *vs. “moderate” and “extensive”; †vs. extensive. FEV1: forced expiratory volume 
in 1 second; FVC: forced vital capacity; RV: residual volume; IC: inspiratory capacity; sRaw: 
specifi c airway resistance; DLCO: lung diffusing capacity for carbon monoxide; V
.
 O2: oxygen 
uptake; V
.
 E: minute ventilation; V
.
 CO2: carbon dioxide output; EILV: end-inspiratory lung 
volume; TLC: total lung capacity; MVC: maximal ventilatory capacity.
Table 2. Selected resting and peak exercise variables in controls and COPD patients separated by PCF tertiles within GOLD grades
GOLD 1
(N= 78)
GOLD 2
(N= 95)
GOLD 3
(N= 75)
GOLD 4
(N =28)
Controls 
(N= 64)
“Mild”
PCF
(N= 59) 
“Moderate” 
PCF
(N= 19)
“Mild”
PCF
(N= 33)
“Moderate” 
PCF
(N= 40)
“Extensive” 
PCF
(N= 22)
“Moderate” 
PCF
(N= 33)
“Extensive” 
PCF
(N= 42)
“Extensive” 
PCF
Rest
FEV1 (% pred) 115.9 ± 14.1 96.1 ± 13.7*† 86.5 ± 6.5* 70.1 ± 8.8*†‡ 61.3 ± 9.0* 55.0 ± 3.5*† 42.5 ± 5.0* 37.7 ± 6.3*† 23.6 ± 3.1*
IC (% pred) 108.2 ± 16.4 107.5 ± 20.0† 90.4 ± 22.6* 94.7 ± 16.1*†‡ 87.6 ± 19.2* 76.5 ± 13.0*† 78.8 ± 14.7* 71.1 ± 18.1*† 51.8 ± 11.6*
IC/TLC 0.47 ± 0.07 0.47 ± 0.09† 0.43 ± 0.10* 0.43 ± 0.08*†‡ 0.38 ± 0.08* 0.35 ± 0.09*† 0.36 ± 0.07* 0.28 ± 0.07*† 0.23 ± 0.07*
RV (% pred) 86.1 ± 17.7 101.2 ± 23.3* 105.1 ± 18.8* 120.7 ± 28.9*†‡ 137.4 ± 26.0* 165.6 ± 30.2*† 167.0 ± 44.8* 195.9 ± 48.0*† 261.6 ± 61.3*
sRaw (abs) 5.29 ± 1.77 8.84 ± 2.80*† 8.70 ± 3.9* 13.4 ± 5.0*†‡ 17.4 ± 7.2* 19.5 ± 8.5*† 17.7 ± 4.7* 24.7 ± 6.7*† 43.5 ± 13.5*
DLCO (% pred) 101.9 ± 21.8 85.9 ± 20.1*† 67.9 ± 23.4* 76.4 ± 22.9*†‡ 68.7 ± 20.1* 54.2 ± 16.4*† 64.1 ± 21.0* 53.2 ± 16.6*† 45.9 ± 17.2*
Peak exercise
V
.
 O2
 % pred 122.3 ± 34.6 94.1 ± 16.0*† 90.9 ± 25.1* 82.2 ± 25.6*†‡ 75.4 ± 21.6* 66.7 ± 12.5*† 67.5 ± 17.2* 56.6 ± 16.9*† 39.5 ± 10.0*
< 1 L/min (%) 0 6.8*
† 55.4* 12.5*†‡ 37.5* 66.7*† 37.5* 64.3*† 85.2*
< 60 % pred (%) 0 5.2*
† 43.8* 9.7*†‡ 19.6* 66.7*† 41.4* 68.1*† 85.2*
V
.
 E/V
.
 CO2 33 ± 5 33 ± 5
† 39 ± 7* 35 ± 4*†‡ 37 ± 5* 42 ± 6*† 35 ± 7* 38 ± 11*† 40 ± 9*
(EILV/TLC)/V
.
E 1.17 ± 0.35 1.51 ± 0.41*
† 2.10 ± 0.64* 1.79 ± 0.57*†‡ 2.23 ± 0.64* 2.91 ± 0.97*† 2.56 ± 0.76* 3.21 ± 0.98*† 4.48 ± 1.32*
(V
.
 E/MVC)/WR 0.28 ± 0.11 0.43 ± 0.14*
† 0.58 ± 0.22* 0.60 ± 0.18*†‡ 0.72 ± 0.21* 0.97 ± 0.32*† 0.75 ± 0.18* 1.01 ± 0.36*† 1.57 ± 0.58*
Dyspnea/V
.
 E 0.05 ± 0.03 0.09 ± 0.05* 0.09 ± 0.04* 0.08 ± 0.04*
†‡ 0.12 ± 0.05* 0.18 ± 0.05*† 0.14 ± 0.07* 0.19 ± 0.10*† 0.23 ± 0.10*
Dyspnea³ Leg (%) 0 5.1*† 26.4* 48.8*†‡ 62.1* 73.9*† 49.5* 69.3*† 78.2*
p < 0.05: *vs. controls, †vs. “moderate”, ‡vs. “moderate” and “extensive.” FEV1: forced expiratory volume in one second; FVC: forced vital capacity; RV: residual volume; IC: inspiratory capac-
ity; sRaw: specifi c airway resistance; DLCO: lung diffusing capacity for carbon monoxide; V
.
 O2: oxygen uptake; V
.
 E: minute ventilation; V
.
 CO2: carbon dioxide output; EILV: end-inspiratory lung 
volume; TLC: total lung capacity; MVC: maximal ventilatory capacity; WR: work rate.
Figure 4. Absolute frequency of the main symptom (leg effort or shortness 
of breath (SOB) reported at the end of progressive exercise in COPD patients 
separated by PCF tertiles.
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 information to standard PFTs to quantify the deleterious 
consequences of uneven resting ventilation on exercise 
capacity in mild-to-advanced COPD.
A solid body of knowledge shows that non-uniformity 
in the behavior of mechanical time constants (resistance ×
compliance) results in asynchronous and inhomoge-
neous ventilation, which can be inferred by the extent 
to which VA underestimates TLC (9–18). Roberts and 
colleagues, for instance, demonstrated that PCF was 
the most sensitive and specifi c gas mixing index to indi-
cate the presence of airfl ow obstruction in 100 COPD 
patients with reduced FEV1 (17). Punjabi et al. showed 
a strong association between the extent of FEV1/FVC 
decrease and PCF increase in a mixed population with 
airway obstruction (18). None of these studies, however, 
attempted to establish the added value of PCF to stan-
dard PFTs within GOLD stages or looked at its func-
tional relevance to dyspnea and exercise intolerance.
In this context, a key finding of the present study 
was the relationship between increased PCF, higher 
dyspnea scores and poorer exercise tolerance (Figures 
4 and 5). It is reasonable to assume that higher resting 
PCF points to non-uniform behavior of mechanical 
time constants of diverse alveolar units (9–18). Our 
results show that the presence of such derangements 
at rest had important implications for the develop-
ment of abnormalities of dynamic mechanics (as sug-
gested by higher ventilation corrected EILC/TLC) and 
ventilatory efficiency (increased V.  E/V.  CO2) under the 
stress of exercise (Table 2). 
Moreover, patients with higher PCF might have an 
exaggerated negative frequency-dependence of resis-
tance and compliance (4,8,32), which might result in 
more asynchronous emptying of lung units. Th us, the 
higher the resting PCF the earlier in exercise the respi-
ratory system reached its physiological limits—either 
expressed as EILV/TLC or V. E/MVC—with associated 
intolerable respiratory discomfort (Table 2). Th ese 
results are increasingly supported by progressive failing 
in proper arterial oxygenation as PCF increased across 
the tertiles.
Another particularly interesting fi nding was the 
increase in PCF in approximately half of the patients 
with mild, grade 1 COPD (30). Of note, Ofi r et al. (2) and 
Guenette et al. (33) demonstrated that exercise ventila-
tory ineffi  ciency (increased V.  E/V.  CO2) was a consistent 
fi nding in these patients despite the lack of increases 
in static lung volumes. In the current study, GOLD 1 
patients with increased PCF had greater ventilatory inef-
fi ciency and dyspnea/V.  E scores. Th ese results suggest a 
mechanistic relationship between excessive ventilatory 
response and resting ventilation distribution inequali-
ties—although we cannot rule out a contributory role of 
a lower PaCO2 setpoint in patients with milder airfl ow 
obstruction. 
It is therefore conceivable that exercise amplifi ed the 
resting ventilation distribution inequalities in GOLD I 
patients with higher PCF thereby increasing the exer-
cise ventilatory requirements. In addition, decreases in 
tidal volume due to higher operating lung volumes (29) 
are likely to further magnify the ventilatory response 
in those patients. Our study, therefore, provides novel 
evidence that PCF increases the sensitivity of FEV1 to 
uncover physiological impairment linked to poorer 
exercise performance in milder COPD.
It is noteworthy that the physiological consequences 
of COPD-related ventilation distribution inequalities 
and increased airway resistance might increase PCF by 
Figure 5. Receiver operating characteristics curve of selected physiological variables to predict a severely reduced peak exercise capacity in COPD patients GOLD grades 
1 to 4 (N = 276). The best PCF cutoff is also highlighted. Defi nition of abbreviations: AUC: area under the curve; CI: confi dence interval; PCF: poorly communicant fraction; 
FEV: forced expiratory volume in 1 second; DLCO: lung diffusing capacity for carbon monoxide; RV: residual volume.
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overestimating TLC by body plethysmography (34,35) 
and/or reducing VA in the DLCO maneuver (14–16). In 
the second scenario, units with longer time constants 
would receive a smaller fraction of the tracer during the 
breath-holding period (36). Th e slower emptying units 
would also contribute less to the sampled expiratory air 
(13–15). 
Apical lung units, which contain lower concentra-
tions of the tracer than basal units, may not be well 
represented in the collected air as they will empty last 
(37). Our results indicate that TLC underestimation was 
indeed the most relevant mechanism for the TLC-VA 
diff erences (Figure 2). In fact, VA might be particularly 
reduced by methane dilution (compared to helium) as 
its lower solubility leads to a steeper methane vs exhaled 
volume relationship in patients with airways obstruc-
tion (21). 
We found substantial variation of PCF for a given 
value of FEV1 (Figure 3A) despite signifi cant associa-
tions between PCF and GOLD stages (Figure 1). Th is 
helps to explain the well-known variation in symptoms 
and exercise tolerance among patients with a similar 
FEV1 (1). Th us, the explanation for this disparity might 
be the fact that gas mixing is predominantly infl uenced 
by small airways function whereas FEV1 is dominated by 
the large airways (32). Consequently, FEV1 might remain 
normal or only slightly decreased in the presence of 
uneven gas mixing in subjects with predominantly small 
airway obstruction (31–33). Obviously, large and small 
airway obstruction may coincide, particularly in more 
severe patients (as reviewed in ref. [5]). Th is might help 
explain the closer association between FEV1 and PCF in 
grade 4 patients (Figure 3A). From a clinical perspective, 
these results suggest that PCF adds more value to FEV1
in less severe patients, i.e., GOLD grades 1 to 3.
Th e present study has, naturally, some strengths and 
limitations. From a positive perspective, this is the larg-
est single study to date to combine respiratory and exer-
cise evaluations (including operating lung volumes and 
dyspnea) across all COPD stages. Moreover, the database 
for the present communication was developed in a ref-
erence laboratory using highly standardized procedures. 
From a pathophysiological point-of-view, however, lack 
of arterial blood gases measurements during exercise 
might have contributed to obscure the potential link 
between increased PCF and worse arterial oxygenation 
and whether PCF would provide an indirect estimate of 
dead space ventilation. Concomitant measurement of 
intra-breath DLCO might also have been useful to esti-
mate whether VA dynamically changed with exercise. 
We were unable to address longitudinal intra-subject 
progressions in PCF and the eff ects of interventions (e.g., 
bronchodilators) upon ventilation distribution inequali-
ties (38). It also remains to be elucidated whether PCF 
might be infl uenced by specifi c disease phenotypes, par-
ticularly the extent of emphysema (39). Future studies 
should also address the modulating eff ects of lung bullae 
(and their specifi c location, i.e., apex vs. lung bases) on 
PCF. Finally, comparison of PCF with more sophisti-
cated—and, presumably, more accurate—tests of venti-
lation distribution heterogeneity (e.g., forced oscillation 
technique (40), multiple-breath nitrogen washout (41)) 
are warranted to further clarify its physiological mean-
ing in diff erent disease stages.
In conclusion, our results support the hypothesis that 
increased resting PCF – which can be readily derived 
from routine body plethysmography (TLC) and single-
breath DLCO measurements (VA)—is associated with 
gas exchange and mechanical abnormalities during 
exercise relevant to dyspnea and exercise intolerance 
across the spectrum of COPD severity. Th e structural 
and pathological determinants of PCF and its potential 
value as a physiological marker of clinical phenotypes, 
disease progression and treatment benefi ts deserve fur-
ther study in this patient population.
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